On February 13, Chief Market Strategist at Carson Group Ryan Detrick and CEO of MCC Global Enterprises Michelle Caruso-Cabrera joined CNBC to discuss rising geopolitical tensions, tariff shifts, and whether tech weakness is a buying opportunity. Detrick shifted the focus to market performance and noted that it is Friday the 13th ahead of the President’s Day long weekend.

Despite the geopolitical tension, he highlighted that the S&P 500 and the Dow have both risen for nine consecutive months on a total return basis. However, he warned that the second half of February is a period where the market could see a 5% dip due to high optimism and put-to-call ratios. Despite this potential short-term slip, he maintained that the bull market remains intact with solid fundamentals.

Caruso-Cabrera added that the market has shifted to a state of indiscriminate selling. She critiqued the current Netflix or Blockbuster mentality and argued that not every AI company will destroy every legacy company. Detrick agreed and pointed out that short interest in the XLK (Tech ETF) has soared to its highest level in years. He revealed that the Carson Group has actually added to tech and software positions and noted that software valuations are at their cheapest since 2013, viewing it as a buying opportunity.

That being said, we’re here with a list of the 10 best growth stocks to buy for the next 20 years.

Our Methodology

We used the Finviz stock screener to find growth stocks with at least 20% EPS growth in the past 5 years and at least 20% expected EPS growth for the next year. We then selected 10 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q3 2025.

Note: All data was sourced on February 18. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

10 Best Growth Stocks to Buy for the Next 20 Years

10. Akebia Therapeutics Inc. (NASDAQ:AKBA)

Number of Hedge Fund Holders: 21

Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the best growth stocks to buy for the next 20 years. On February 6, Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Akebia to $4 from $6 and kept an Overweight rating. This adjustment was made as part of a broader review of commercial-stage companies, with the firm updating estimates and price targets following several year-end preliminary reports and ahead of official Q4 2025 results.

In Q3, Akebia Therapeutics Inc. (NASDAQ:AKBA) reported total revenue of $58.8 million with a net income of $540,000, successfully pivoting from a $20 million net loss in Q3 2024. While the launch of its dialysis drug Vafseo saw lower-than-expected revenue of $14.3 million due to operational and adherence hurdles, the company expanded its patient access to 70,000 and reached a milestone of over 700 active prescribers.

Despite an anticipated temporary revenue dip in Q4 due to inventory adjustments at US Renal Care, management projects growth to resume in Q1 2026. The company remains focused on its 2026 pipeline outlook, including the initiation of a Phase 2 rare kidney disease study, while maintaining that its current cash reserves are sufficient to fund its path toward sustained profitability.

Akebia Therapeutics Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes therapeutics for patients with kidney diseases.

9. LiveRamp Holdings Inc. (NYSE:RAMP)

Number of Hedge Fund Holders: 27

LiveRamp Holdings Inc. (NYSE:RAMP) is one of the best growth stocks to buy for the next 20 years. On February 6, DA Davidson lowered its price target on LiveRamp to $35 from $45 with a Buy rating. Although the company exceeded top and bottom-line expectations in FQ3 2026, management left its fiscal year 2026 guidance unchanged. The analyst attributed this cautious outlook to the timing of specific project-based expenses shifting into FQ4 and marketplace growth that came in softer than previously anticipated.

In its FQ3 earnings report posted a day prior, LiveRamp Holdings Inc. (NYSE:RAMP) announced revenue growth of 9% year-over-year to $212 million. Management highlighted a significant strategic partnership with Publicis and the expansion of its Data Marketplace to include AI models and agents, which they believe positions the firm for double-digit growth in fiscal year 2027.

While the company is successfully growing its high-value million-dollar-plus accounts, subscription net retention compressed to 101%, and gross margins are expected to dip slightly as backend platform upgrades conclude. Looking ahead to FQ4, LiveRamp projected a sequential increase in operating expenses of $15 million due to seasonal events and compensation adjustments, while providing a full-year revenue guidance range of $810 million to $814 million.

LiveRamp Holdings Inc. (NYSE:RAMP) is a technology company that operates a data collaboration platform in the US, Europe, the Asia-Pacific, and internationally.